Navigation Links
New Trial Presented at AAAAI Reports that the Growth of Children 2-5 Years Old with Year-Round Allergic Rhinitis Continued According to Normal Age-Adjusted Distribution Over a 6-Month Treatment with Nasacort AQ
Date:3/15/2008

BRIDGEWATER, N.J., March 15 /PRNewswire-FirstCall/ -- Data presented at the annual meeting of the American Academy of Allergy Asthma & Immunology (AAAAI) suggests that the continuous use of intranasal corticosteroid Nasacort AQ (triamcinolone acetonide) Nasal Spray had no treatment effect on stature-for age distribution among children aged 2-5 years old with year-round allergic rhinitis.

"Continuous use of intranasal corticosteroids in the treatment of very young children with allergic rhinitis has in the past raised concerns regarding potential effects on growth," said study investigator Dr. Paul Ratner, Medical Director, Sylvana Research Associates, San Antonio, Texas. "I am encouraged by the results which showed that following 6 month treatment with Nasacort AQ, the stature-for-age distribution did not appear to shift compared to pretreatment in children aged 2-5 years who suffer from year-round allergies."

This is one of the first controlled studies in the U.S. designed to investigate both the efficacy and safety of intranasal corticosteroid treatment in children aged 2-5 years with year-round allergies. The trial included a four-week, multicenter, double-blind treatment period during which 433 children were randomized to receive either Nasacort AQ 110 micrograms or placebo as 1 spray per nostril once daily. After four weeks, 353 patients entered into a 6-month open label phase receiving treatment with once-daily Nasacort AQ. Height was measured at Visit 1 to establish a baseline, Visit 4 after the initial 4 weeks, and Visit 8 when the 6-month open label period completed. The treatment-emergent adverse event profile was similar between the Nasacort AQ group and placebo group, and consistent with the profile in children 6 years of age and older. To participate in the study, patients had to have year-round allergic rhinitis.

Height was measured at each office visit using a stadiometer, an instrument for measuring height. After the four-
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
2. Northern California Foot and Ankle Center Santa Rosa Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Research Trial
3. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
4. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
5. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
6. PARI Nebulizer & Compressor Used Exclusively in Inspires Phase 3 CF Trial
7. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
8. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
9. Multi Merci Trial Results Published in Peer Reviewed Journal
10. Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)...  Chuma Holdings, Inc. (OTCBB:CHUM) (the "Company"), an ... services for the lawfully organized cannabis industry, is ... the Company,s name and symbol change request. Effective ... known as Chuma Holdings, Inc. ... with the Company,s wholly-owned subsidiary, Chuma Holdings, Inc., ...
(Date:8/29/2014)... 29, 2014  A Boston Scientific Corporation (NYSE: ... stent removability and preliminary long term stricture resolution ... the August issue of the peer-reviewed journal, Gastroenterology. ... is being conducted in 11 countries and five ... metal stents (FCSEMS) after extended indwell (i.e., up ...
(Date:8/29/2014)... Research and Markets has announced the addition ... report to their offering. Benefiting ... for medical expenses, the Chinese orthopedic instrument market demand ... CAGR of 19.2% during 2009-2013. Trauma products, spine products ... instruments in China , of which ...
Breaking Medicine Technology:CannaMed Announces Name Change and Trading Symbol Change 2CannaMed Announces Name Change and Trading Symbol Change 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4China Orthopedic Instrument Industry Report, 2014-2017 2
... - Inovio Biomedical,Corporation (AMEX:INO), focused on the ... diseases and a novel alternative to,surgery to ... partner, Vical Incorporated, presented positive interim,safety and ... ongoing Phase I,clinical trial using Inovio's electroporation ...
... Clinical results from a,Phase II study presented ... Society (AHS) annual meeting showed that MK-0974, ... significantly improved migraine pain relief,two hours after ... was,sustained through 24 hours. MK-0974 was generally ...
Cached Medicine Technology:Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 2Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 3Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 4Vical Interim Clinical Results Demonstrate Safety and Tolerability,of Inovio Biomedical's Electroporation DNA Delivery Technology 5Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 2Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 3Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 4Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 5
(Date:8/30/2014)... August 30, 2014 Market Research ... 2009-2019 is a professional and in-depth market survey ... report firstly reviews the basic information of Cell ... The report then explores global and China’s top ... capacity, Production value, and market share etc. The ...
(Date:8/30/2014)... 2014 Insomnia causes disturbances in every aspect ... they unknowingly developed insomnia and the steps often used to ... Tune in to the show at this link: Dr. ... on August 30, and will be podcasted at this ... to DrCarolFrancisTalkRadio.com. , "Insomnia causes countless unrecognized complications. ...
(Date:8/30/2014)... In today’s world, a good night’s sleep ... and sleep apnea (a medical problem where the airway collapses ... partners of the rest they need to face their daily ... and 20 million people in the United States alone have ... treated; and of those treated, many cannot tolerate their prescribed ...
(Date:8/30/2014)... commonly used to treat gout, before and after ... complications from this type of surgery, but it ... according to a study published by JAMA ... to coincide with its presentation at the European ... cardiac surgery include postpericardiotomy syndrome (the occurrence of ...
(Date:8/30/2014)... York (PRWEB) August 30, 2014 Serving ... company in India, Profit By Outsourcing is now ... Development services. The company gives emphasize on putting forward ... complete product to clients. Their dedicated team of professionals ... ground-breaking results. They can handle even the critical issues ...
Breaking Medicine News(10 mins):Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 2Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 3Health News:Cell Disruptor Industry Global and Chinese Analysis for 2009-2019 in New Research Report at ReportsnReports.com 4Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Medication shows mixed results in reducing complications from cardiac surgery 2Health News:Profit By Outsourcing Offering Discount for Labor Day on all Web Development Services 2
... Solutions for Medical Equipment, Building Infrastructure and Automation, ... NEW YORK, March 23 Via Christi Health ... a wide range of technology and service solutions ... Christi Health System,s strategic plan.(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO ...
... Siemens Financial Services, Inc. announced today that ... to El Camino Hospital in Mountain View, California. ... a variety of Siemens Medical Solutions equipment which ... hospital under construction.(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )"For more ...
... Education Virtual Lecture for Healthcare ProfessionalsVOORHEES, N.J., March ... infection (CDI) is changing rapidly and has ... and severity. Management of CDI can be challenging ... updated. In order to effectively implement key strategies ...
... WASHINGTON, March 23 March 22 was World Water ... of the 1992 United Nations Conference on Environment and ... of World Water Day this year is Transboundary Waters: ... the Poor Act of 2005 makes access to safe ...
... MBF Healthwatch survey has revealed that a disturbing number of ... they are ,too tired, or ,can,t be bothered, having a ... 22% of parents interviewed said their children skip breakfast on ... further 20% skip breakfast on one or two school days. ...
... get relief from their symptoms and the psychological distress ... , Skin experts and psychologists at The University of ... known as ,electronic Targeted Intervention for Psoriasis, or eTIPS ... better. , "Psoriasis is a skin disease that usually ...
Cached Medicine News:Health News:Via Christi Health System and Siemens Announce Technology Alliance 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 2Health News:Siemens Financial Services, Inc. Announces Completion of Tax-Exempt Financing With El Camino Hospital 3Health News:Clostridium difficile Infection in Primary Care: Tackling a Virulent Pathogen 2Health News:USAID World Water Day Statement 2Health News:USAID World Water Day Statement 3Health News:School kids 'wagging' breakfast are missing healthy brain fuel 2Health News:Experts turn to Web to combat distressing skin disease 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: